HCA Gives $1 Million in Aid for Ebola Response

Myeloma Research To Be Presented At The American Society of Clinical Oncology's 47th Annual Meeting (ASCO 2011)

May 27, 2011

Dr. Jesus Berdeja to present results from a Phase 1 study of lorvotuzumab mertansine in combination with Revlimid and dexamethasone in a specific subset of relapsed / refractory myeloma patients whose myeloma cells contain the CD56 protein.

Please click here for more details.